Transasia Bio-Medicals eyeing $! billion revenues, 70% from overseas

Company planning for IPO to fund overseas acquisitions worth nearly Rs 3,000 crore

Leading In-Vitro Diagnostic (IVD) solutions company Transasia Bio-Medicals is eyeing revenues of about $1 billion in the next 5 years, of which 70% is projected to accrue from overseas.

Currently, the overseas business contributes nearly 40 per cent to the top line of the company, which clocked Rs 1,300 crore in revenues during 2018-19, chairman and managing director Suresh Vazirani told Business Standard in Lucknow, adding in the current financial year, Transasia was expecting a 15 per cent uptick in turnover at Rs 1,500 crore.

He said overseas revenues were growing faster than domestic, since the company had acquired leading R&D firms